免疫逃逸相关分子B7-H1影响恶性肿瘤多药耐药的研究进展
|
摘要
肿瘤多药耐药是目前肿瘤治疗失败的主要原因之一,也是肿瘤治疗领域的重要问题。随着对肿瘤免疫微环境方面的研究不断进行,肿瘤免疫逃逸的地位得以深入理解,其中相关分子B7-H1的异常表达与肿瘤耐药发生之间的密切关系不断被认识,其表现在耐药肿瘤可能较非耐药肿瘤细胞更易逃逸机体的免疫系统监视和杀伤。文章主要对免疫逃逸相关分子B7-H1影响恶性肿瘤多药耐药研究进展进行综述。
Malignant tumors with multidrug resistance is one of the major reasons for the failure of tumor treatment,and it is also an important issue in the field of cancer treatment. In recent years,with the continuous research on tumor immune microenvironment,the status of tumor immune escape is deeply understood. The close relationship between the abnormal expression of related molecules B7-H1 and tumor resistance is constantly recognized that multidrug resistant tumor may be more sensitive to immune system surveillance and killing than chemotherapy-sensitive tumor. The article reviews the progress of immune escape-related molecule B7-H1 in multidrug resistance of malignant tumors.
Malignant tumors with multidrug resistance is one of the major reasons for the failure of tumor treatment,and it is also an important issue in the field of cancer treatment. In recent years,with the continuous research on tumor immune microenvironment,the status of tumor immune escape is deeply understood. The close relationship between the abnormal expression of related molecules B7-H1 and tumor resistance is constantly recognized that multidrug resistant tumor may be more sensitive to immune system surveillance and killing than chemotherapy-sensitive tumor. The article reviews the progress of immune escape-related molecule B7-H1 in multidrug resistance of malignant tumors.
引文
[1]Huang Y,Cole S,Cai T,et al.Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer(Review)[J].Oncol Lett,2016:12(1):11-15.
[2]Du B,Shim JS.Targeting Epithelial-Mesenchymal Transition(EMT)to Overcome Drug Resistance in Cancer[J].Molecules,2016,21(7):965.
[3]Gillet JP,Gottesman MM.Mechanisms of Multidrug Resistance in Cancer[J].Methods Mol Biol,2010,596(596):47-76.
[4]Kim JM,Chen DS.Immune escape to PD-L1/PD-1 blockade:seven steps to success(or failure)[J].Ann Oncol,2016,27(8):1492-1504.
[5]Mahoney KM,Sun H,Liao X,et al.Antibodies to the cytoplasmic domain of PD-L1 most clearly delineate cell membranes in immunohistochemical staining[J].Cancer Immunol Res,2015,3(12):1308-1315.
[6]Bertucci F,Finetti P,Colpaert C,et al.PD-L1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy[J].Oncotarget,2015,6(15):13506-13519.
[7]Patel SP,Kurzrock R.PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.[J].Mol Cancer Ther,2015,14(4):847-856.
[8]Shi SJ,Wang LJ,Wang GD,et al.B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells[J].PLoS One,2013,8(10):e76012-.
[9]Velcheti V,Schalper KA,Carvajal DE,et al.Programmed death ligand-1 expression in non-small cell lung cancer[J].Lab Invest,2014,94(1):107-116.
[10]Mu CY,Huang JA,Chen Y,et al.High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation[J].Med Oncol,2011,28(3):682-688.
[11]Chikuma S.Basics of PD-1 in self-tolerance,infection,and cancer immunity[J].Int J Clin Oncol,2016,21(3):448-455.
[12]Taube JM,Klein A,Brahmer JR,et al.Association of PD-1,PD-1 Ligands,and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy[J].Clin Cancer Res,2014,20(19):5064-5074.
[13]Zou W,Chen L.Inhibitory B7-family molecules in the tumour microenvironment[J].Nat Rev Immunol,2008,8(6):467-477.
[14]Ock CY,Kim S,Keam B,et al.PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma[J].Oncotarget,2016,7(13):15901-15914.
[15]Cao Y,Zhang L,Kamimura Y,et al.B7-H1 Overexpression Regulates Epithelial-Mesenchymal Transition and Accelerates Carcinogenesis in Skin[J].Cancer Res,2011,71(4):1235-1243.
[16]Alsuliman A,Colak D,Al-Harazi O,et al.Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition:Significance in claudin-low breast cancer cells[J].Mol Cancer,2015,14(1):149.
[17]Wang Y,Wang H,Zhao Q,et al.PD-L1 induces epithelial-tomesenchymal transition via activating SREBP-1c in renal cell carcinoma[J].Med Oncol,2015,32(8):212.
[18]Tsutsumi S,Saeki H,Nakashima Y,et al.Programmed deathligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma[J].Cancer Sci,2017,108(6):1119.
[19]Noman MZ,Janji B,Abdou A,et al.The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200[J].Oncoimmunology,2017,6(1):e1263412.
[20]Ueno T,Tsuchikawa T,Hatanaka KC,et al.Prognostic impact of programmed cell death ligand 1(PD-L1)expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma[J].Oncotarget,2018,9(28):20034-20047.
[21]Ock C Y,Kim S,Keam B,et al.PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma[J].Oncotarget,2016,7(13):15901-15914.
[22]Asiedu MK,Ingle JN,Behrens MD,et al.TGFβ/TNFα-Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype[J].Cancer Res,2011,71(13):4707-4719.
[23]Li W,Liu C,Tang Y,et al.Overexpression of snail accelerates adriamycin induction of multidrug resistance in breast cancer cells[J].Asian Pac J Cancer Prev,2011,12(10):2575-2580.
[24]Dong J,Zhai B,Sun W,et al.Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells[J].PLoS One,2017,12(9):e0185088.
[25]Ishibashi M,Tamura H,Sunakawa M,et al.Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1(PD-L1)to PD-1[J].Cancer Immunol Res,2016,4(9):779-788.
[26]Kraak LVD,Goel G,Ramanan K,et al.5-Fluorouracil upregulates cell surface B7-H1(PD-L1)expression in gastrointestinal cancers[J].J Immuno Ther Cancer,2016,4(1):65.
[27]Tamura H,Ishibashi M,Yamashita T,et al.Marrow stromal cells induce B7-H1 expression on myeloma cells,generating aggressive characteristics in multiple myeloma[J].Leukemia,2013,27(2):464-472.
[28]刘鸿飞,赵帅,吴晓鎏,等.负性共刺激分子B7-H1与乳腺癌细胞化疗敏感性的关系研究[J].中国临床医生,2016,12:69-72.
[29]Liu S,Chen S,Yuan W,et al.PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways[J].Oncotarget,2017,8(59):99901-99912.
[30]满忠松,汤在祥,周进,等.程序性细胞死亡配体1状态与乳腺癌放疗敏感性的关系[J].医学研究生学报,2019,32(2):198-203.
[31]陈美姿,张方,宋勇.可溶性PD-L1在恶性肿瘤中的临床研究进展[J].医学研究生学报,2018,31(3):323-327.
[32]李欣颖,张方,宋勇.PD-L1与Treg细胞在肿瘤免疫中的作用及联系[J].医学研究生学报,2018,31(2):198-203.
[2]Du B,Shim JS.Targeting Epithelial-Mesenchymal Transition(EMT)to Overcome Drug Resistance in Cancer[J].Molecules,2016,21(7):965.
[3]Gillet JP,Gottesman MM.Mechanisms of Multidrug Resistance in Cancer[J].Methods Mol Biol,2010,596(596):47-76.
[4]Kim JM,Chen DS.Immune escape to PD-L1/PD-1 blockade:seven steps to success(or failure)[J].Ann Oncol,2016,27(8):1492-1504.
[5]Mahoney KM,Sun H,Liao X,et al.Antibodies to the cytoplasmic domain of PD-L1 most clearly delineate cell membranes in immunohistochemical staining[J].Cancer Immunol Res,2015,3(12):1308-1315.
[6]Bertucci F,Finetti P,Colpaert C,et al.PD-L1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy[J].Oncotarget,2015,6(15):13506-13519.
[7]Patel SP,Kurzrock R.PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.[J].Mol Cancer Ther,2015,14(4):847-856.
[8]Shi SJ,Wang LJ,Wang GD,et al.B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells[J].PLoS One,2013,8(10):e76012-.
[9]Velcheti V,Schalper KA,Carvajal DE,et al.Programmed death ligand-1 expression in non-small cell lung cancer[J].Lab Invest,2014,94(1):107-116.
[10]Mu CY,Huang JA,Chen Y,et al.High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation[J].Med Oncol,2011,28(3):682-688.
[11]Chikuma S.Basics of PD-1 in self-tolerance,infection,and cancer immunity[J].Int J Clin Oncol,2016,21(3):448-455.
[12]Taube JM,Klein A,Brahmer JR,et al.Association of PD-1,PD-1 Ligands,and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy[J].Clin Cancer Res,2014,20(19):5064-5074.
[13]Zou W,Chen L.Inhibitory B7-family molecules in the tumour microenvironment[J].Nat Rev Immunol,2008,8(6):467-477.
[14]Ock CY,Kim S,Keam B,et al.PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma[J].Oncotarget,2016,7(13):15901-15914.
[15]Cao Y,Zhang L,Kamimura Y,et al.B7-H1 Overexpression Regulates Epithelial-Mesenchymal Transition and Accelerates Carcinogenesis in Skin[J].Cancer Res,2011,71(4):1235-1243.
[16]Alsuliman A,Colak D,Al-Harazi O,et al.Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition:Significance in claudin-low breast cancer cells[J].Mol Cancer,2015,14(1):149.
[17]Wang Y,Wang H,Zhao Q,et al.PD-L1 induces epithelial-tomesenchymal transition via activating SREBP-1c in renal cell carcinoma[J].Med Oncol,2015,32(8):212.
[18]Tsutsumi S,Saeki H,Nakashima Y,et al.Programmed deathligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma[J].Cancer Sci,2017,108(6):1119.
[19]Noman MZ,Janji B,Abdou A,et al.The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200[J].Oncoimmunology,2017,6(1):e1263412.
[20]Ueno T,Tsuchikawa T,Hatanaka KC,et al.Prognostic impact of programmed cell death ligand 1(PD-L1)expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma[J].Oncotarget,2018,9(28):20034-20047.
[21]Ock C Y,Kim S,Keam B,et al.PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma[J].Oncotarget,2016,7(13):15901-15914.
[22]Asiedu MK,Ingle JN,Behrens MD,et al.TGFβ/TNFα-Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype[J].Cancer Res,2011,71(13):4707-4719.
[23]Li W,Liu C,Tang Y,et al.Overexpression of snail accelerates adriamycin induction of multidrug resistance in breast cancer cells[J].Asian Pac J Cancer Prev,2011,12(10):2575-2580.
[24]Dong J,Zhai B,Sun W,et al.Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells[J].PLoS One,2017,12(9):e0185088.
[25]Ishibashi M,Tamura H,Sunakawa M,et al.Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1(PD-L1)to PD-1[J].Cancer Immunol Res,2016,4(9):779-788.
[26]Kraak LVD,Goel G,Ramanan K,et al.5-Fluorouracil upregulates cell surface B7-H1(PD-L1)expression in gastrointestinal cancers[J].J Immuno Ther Cancer,2016,4(1):65.
[27]Tamura H,Ishibashi M,Yamashita T,et al.Marrow stromal cells induce B7-H1 expression on myeloma cells,generating aggressive characteristics in multiple myeloma[J].Leukemia,2013,27(2):464-472.
[28]刘鸿飞,赵帅,吴晓鎏,等.负性共刺激分子B7-H1与乳腺癌细胞化疗敏感性的关系研究[J].中国临床医生,2016,12:69-72.
[29]Liu S,Chen S,Yuan W,et al.PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways[J].Oncotarget,2017,8(59):99901-99912.
[30]满忠松,汤在祥,周进,等.程序性细胞死亡配体1状态与乳腺癌放疗敏感性的关系[J].医学研究生学报,2019,32(2):198-203.
[31]陈美姿,张方,宋勇.可溶性PD-L1在恶性肿瘤中的临床研究进展[J].医学研究生学报,2018,31(3):323-327.
[32]李欣颖,张方,宋勇.PD-L1与Treg细胞在肿瘤免疫中的作用及联系[J].医学研究生学报,2018,31(2):198-203.